IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by UBS Group

UBS Group initiated coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report published on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $50.00 price target on the stock.

A number of other equities analysts have also issued reports on IDYA. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. BTIG Research boosted their price objective on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Citigroup dropped their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 27th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Finally, Stifel Nicolaus boosted their target price on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Buy” and a consensus target price of $55.45.

IDEAYA Biosciences Trading Up 6.2 %

Shares of NASDAQ:IDYA opened at $31.00 on Thursday. The firm has a 50 day simple moving average of $34.50 and a 200-day simple moving average of $37.60. The company has a market capitalization of $2.35 billion, a PE ratio of -14.53 and a beta of 0.82. IDEAYA Biosciences has a twelve month low of $25.22 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same period in the prior year, the business earned ($0.50) earnings per share. As a group, equities research analysts predict that IDEAYA Biosciences will post -2.51 EPS for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Allworth Financial LP increased its stake in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 800 shares during the last quarter. Covestor Ltd grew its stake in IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the period. Quest Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the second quarter worth $41,000. Comerica Bank raised its stake in shares of IDEAYA Biosciences by 723.5% in the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after acquiring an additional 1,324 shares during the period. Finally, JTC Employer Solutions Trustee Ltd acquired a new position in shares of IDEAYA Biosciences during the 1st quarter valued at $67,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.